I think all these therapies have improved survival versus our old standard of care sorafenib, which has been the comparative use in all these phase III studies, with increasing overall survival response rate and PFS in gen...
SOR是第一个被证明对晚期HCC临床治疗有效小分子TKI类靶向药[6],根据SHARP研究,与安慰剂组相比,SOR延长患者中位总生存(median overall survival,mOS)时间2.8个月[6],但在随后的ORIENTAL研究中,SOR仅延长患者mOS时间1.3个月。其原因可能与...
[9]Morimoto M, Numata K, Kondo M, Hidaka H, Takada J, Shibuya A, et al. Higher discontinuation and lower survival rates are likely in elderly Japanese patients with advanced hepatocellular carcinoma receiving sorafenib. Hepatol Res. 2011;41(4):296–302. [10]Montella L, Addeo R, Cennamo ...
“The forest plot of overall survival by subgroup in patients with baseline AFP above 400 clearly and numerically shows a favorable outcome with ramucirumab for overall survival in all subgroups tested,” Zhu noted. “The overall survival decreases in both [ramucirumab and placebo] arms as increasin...
中国学者比较了开腹、腹腔镜和机器人辅助肝切除治疗BCLC 0~A期HCC患者的无病生存期(disease-free survival,DFS)和总生存期(overall survival,OS),发现三种手术方式的患者预后差异无统计学意义(OS率分别为80.8%、78.6%和75.7%,DFS率分别为63.8%、54.4%和50.6%)[56]。此外,吲哚菁绿分子荧光影像、三维可视化、增强...
In the study, the 1-, 3-, and 4-year survival rates were similar between the treatment modalities, said Anne Covey, MD, who presented the guideline at the meeting. “The guidelines have most recently changed to include ablation as a potentially curative option,” Covey, attending radiologist...
Natural history of small untreated hepatocellular carcinoma in cirrhosis: a multivariate analysis of prognostic factors of tumor growth rate and patient survival Hepatology, 16 (1992), pp. 132-137 CrossrefView in ScopusGoogle Scholar [19] European Association for the Study of the Liver EASL clinical...
survival rates of over 60% can be reached. Such early diagnosis is a reality only in a minority of patients, however, and in the majority of cases the disease is already in an advanced stage at diagnosis. One of the objects of HCC screening is diagnosis in an early stage when curative ...
Lencioni R, Paolicchi A, Moretti M et al (1998) Combined transcatheter arterial chemoembolization and percutaneous ethanol injection for the treatment of large hepatocellular carcinoma: local therapeutic effect and longterm survival rate. Eur Radiol 8:439–444 Article PubMed CAS Google Scholar Lencio...
根据mRECIST 以及 EASL 评价标准等评估肝癌局部疗效, 长期疗效指标为患者总生存时间(Overall survival, OS);短期疗效为客观缓解率(Objective response rate, ORR)、 TACE 治疗至疾病进展时间。 7.影响 TACE 远期疗效的主要因素[193]。 ...